how big is Veerhealth Care?

As of Jun 06, Veerhealth Care Ltd has a market capitalization of 29.04 Cr, with net sales of 16.67 Cr and a net profit of 0.39 Cr for the latest four quarters. Shareholder's funds are 21.84 Cr, and total assets amount to 28.12 Cr as of Mar'24.

Market Cap: As of Jun 06, Veerhealth Care Ltd has a market capitalization of 29.04 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Veerhealth Care reported net sales of 16.67 Cr and a net profit of 0.39 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also Standalone and pertains to the latest annual period ending in Mar'24. Shareholder's funds are reported at 21.84 Cr, while total assets amount to 28.12 Cr.

When is the next results date for Veerhealth Care?

No Upcoming Board Meetings

Who are in the management team of Veerhealth Care?

As of March 2022, the management team of Veerhealth Care includes Shruti Y Shah (Executive Director), Bhavin S Shah (Managing Director), and several independent and non-executive directors, with varying remuneration levels. The team is responsible for the governance and management of the company.

As of March 2022, the management team of Veerhealth Care includes the following individuals:<BR><BR>1. Shruti Y Shah - Executive Director (Remuneration: Rs. 5.2 lacs)<BR>2. Arvind M Shah - Independent Director (Remuneration: Rs. 1.0 k)<BR>3. Yogesh M Shah - Chairman & Independent Director (Remuneration: Rs. 0)<BR>4. Bhavin S Shah - Managing Director (Remuneration: Rs. 9.6 lacs)<BR>5. Dharnendra B Shah - Independent Director (Remuneration: Rs. 1.0 k)<BR>6. Mitesh J Kuvadia - Independent Director (Remuneration: Rs. 2.0 k)<BR>7. Rony M Shah - Company Secretary & Compliance Officer (Remuneration: Rs. 5.72 lacs)<BR>8. Chetan H Mehta - Non-Executive Director (Remuneration: Rs. 0)<BR>9. Prakash C Shah - Non-Executive Director (Remuneration: Rs. 0)<BR>10. Nilesh Kantilal Shah - Non-Executive Director (Remuneration: Rs. 0)<BR><BR>This team comprises a mix of executive, independent, and non-executive directors, each contributing to the governance and management of the company.

What does Veerhealth Care do?

Veerhealth Care Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally incorporated in 1992 and renamed in 2013. As of March 2025, it reported net sales of 6 Cr and a market cap of Rs 30 Cr.

Overview:<BR>Veerhealth Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated on 10 July, 1992, as Niyati Leasing Limited. It underwent several name changes, first to Niyati Industries Limited in 1998 and then to Veerhealth Care Limited in May 2013. The latest quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 6 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 30 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 30<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.17<BR>- Return on Equity: 1.76%<BR>- Price to Book: 1.35<BR><BR>Contact Details:<BR>Address: 629-A 1st Floor Gazdar House, JSS Marg Nr Kalbadevi Post Off Mumbai Maharashtra : 400002<BR>Tel: 91-22-22018582<BR>Email: info@veerhealthcare.net<BR>Website: http://www.veerhealthcare.net

What is the bonus history of the Veerhealth Care?

Veerhealth Care recently issued a 1:1 bonus share on September 22, 2023, meaning shareholders received an additional share for each share held. The record date for this bonus was also September 22, 2023.

Veerhealth Care has a recent bonus history that includes a 1:1 bonus issue announced with an ex-date of September 22, 2023. This means that for every share held, shareholders received an additional share. The record date for this bonus was also September 22, 2023. If you have any more questions about Veerhealth Care or need further details, feel free to ask!

Has Veerhealth Care declared dividend?

No Dividend History Available

Who are the peers of the Veerhealth Care?

Veerhealth Care's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Colinz Labs, Vineet Laborator, Zenith Health, and Ishita Drugs. It has below-average management risk and growth compared to its peers, with a 1-year return of -23.83%.

Peers: The peers of Veerhealth Care are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Colinz Labs, Vineet Laborator, Zenith Health, and Ishita Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is seen at Veerhealth Care, Colinz Labs, Zenith Health, Ishita Drugs, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Veerhealth Care, Colinz Labs, Vineet Laborator, Zenith Health, Ishita Drugs, and the rest. Excellent capital structure is present at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, Veerhealth Care, Colinz Labs, Zenith Health, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the peer with the lowest is Vineet Laborator at -46.35%. Veerhealth Care's 1-year return is -23.83%, which is higher than Vineet Laborator's but lower than all other peers. Additionally, the six-month return is negative for Veerhealth Care, Cipla, Torrent Pharma, Dr Reddy's Labs, Vineet Laborator, Zenith Health, and Ishita Drugs.

Is Veerhealth Care overvalued or undervalued?

As of February 13, 2025, Veerhealth Care is considered overvalued with a PE ratio of 30.00 and an EV to EBITDA of 33.75, despite recent strong stock performance, indicating a shift in sentiment from very expensive to risky compared to peers like Elitecon International and Lloyds Enterprises.

As of 13 February 2025, Veerhealth Care's valuation grade has moved from very expensive to risky, indicating a shift in investor sentiment. The company is currently assessed as overvalued. Key ratios include a PE ratio of 30.00, an EV to EBITDA of 33.75, and a ROE of 1.76%. <BR><BR>In comparison to its peers, Veerhealth Care's PE ratio is significantly lower than that of Elitecon International, which stands at 131.08, and also lower than Lloyds Enterprises at 156.59. However, it is on par with MMTC, which has a PE ratio of 119.39. Notably, the company's recent stock performance has outpaced the Sensex in the short term, with a 1-week return of 9.80% compared to the Sensex's 1.43%. This suggests some short-term investor interest, but the overall valuation still leans towards overvaluation given the broader financial metrics.

What is the technical trend for Veerhealth Care?

As of May 12, 2025, Veerhealth Care shows a mildly bearish trend overall, with mixed indicators suggesting short-term weakness despite a current price of 16.47, which is above the previous close of 15.00.

As of 12 May 2025, the technical trend for Veerhealth Care has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD indicates a mildly bearish stance. The moving averages on a daily basis are also mildly bearish, suggesting short-term weakness. Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish monthly. The KST reflects a mildly bullish trend weekly while being mildly bearish monthly. Overall, the indicators present a mixed picture, with a slight bearish bias prevailing in the longer term. The current price of 16.47 is above the previous close of 15.00, but the stock has underperformed significantly over the past year. The overall stance is mildly bearish with moderate strength.

Who are the top shareholders of the Veerhealth Care?

The top shareholder of Veerhealth Care is Yogesh Mahasuklal Shah, with an 11.03% stake, followed by public shareholder Deval Nilay Shah at 2.68%. Individual investors collectively own 57.92% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Veerhealth Care include Yogesh Mahasuklal Shah, who holds the highest stake at 11.03%. The highest public shareholder is Deval Nilay Shah, with a holding of 2.68%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 57.92% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Are Veerhealth Care latest results good or bad?

Veerhealth Care's latest results are concerning, showing a slight profit increase but significant revenue declines of 11.36% quarter-on-quarter and 22.72% year-on-year, alongside low profitability metrics. Overall, the financial outlook suggests ongoing challenges in achieving consistent growth.

Veerhealth Care's latest results present a mixed picture, leaning towards the negative side. In Q2 FY26, the company reported a net profit of ₹0.25 crores, which is a slight increase of 4.17% from the previous quarter. However, this figure represents a significant decline of 16.67% compared to the same quarter last year. <BR><BR>Revenue for the same period was ₹3.98 crores, reflecting a concerning drop of 11.36% quarter-on-quarter and a substantial decline of 22.72% year-on-year. This ongoing revenue contraction indicates serious challenges in maintaining market traction and suggests that the company is struggling to achieve consistent growth in a competitive pharmaceutical landscape.<BR><BR>While the operating margin improved to 13.32%, up from -0.67% in the previous quarter, this improvement is overshadowed by the revenue decline and raises questions about the sustainability of profitability. The company's overall performance is further complicated by its low return on equity of 2.72% and negative return on capital employed, indicating inefficiencies in generating returns from its investments.<BR><BR>Given these factors, the financial outlook for Veerhealth Care appears troubling, with persistent revenue challenges and weak profitability metrics suggesting that the latest results are more indicative of underlying issues rather than a positive turnaround.

How has been the historical performance of Veerhealth Care?

Veerhealth Care's historical performance shows net sales growth from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, but profitability has fluctuated, with profit after tax declining from 1.58 Cr in Mar'23 to 0.39 Cr in Mar'25. Total assets increased significantly, while cash flow from operating activities dropped to 0.00 Cr in Mar'25.

Answer:<BR>The historical performance of Veerhealth Care shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Veerhealth Care's net sales have increased from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, rising from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25. The company's total expenditure also grew, reaching 16.21 Cr in Mar'25 from 10.45 Cr in Mar'22. Operating profit (PBDIT) fluctuated, peaking at 2.00 Cr in Mar'24 before dropping to 1.68 Cr in Mar'25. Profit before tax showed variability, with a notable increase to 1.28 Cr in Mar'24 but declining to 0.51 Cr in Mar'25. Profit after tax was 0.39 Cr in Mar'25, down from 1.58 Cr in Mar'23. The company's total assets increased significantly from 20.15 Cr in Mar'22 to 33.77 Cr in Mar'25, while total liabilities also rose from 20.15 Cr to 33.77 Cr in the same period. Cash flow from operating activities was 0.00 Cr in Mar'25, contrasting with 2.00 Cr in Mar'24, while cash flow from investing activities showed a negative trend at -8.00 Cr in Mar'25. Overall, Veerhealth Care's financial performance reflects both growth in sales and assets, alongside challenges in profitability and cash flow management.

Should I buy, sell or hold Veerhealth Care?

Which are the latest news on Veerhealth Care?

Why is Veerhealth Care falling/rising?

As of 03-Dec, Veerhealth Care Ltd's stock is slightly rising at 18.99, with a 0.26% increase today, but has declined 3.65% YTD, indicating longer-term challenges despite short-term gains. The stock is above several moving averages, suggesting a bullish trend, yet decreased investor participation raises concerns about confidence.

As of 03-Dec, Veerhealth Care Ltd's stock price is rising slightly, with a current price of 18.99, reflecting a change of 0.05 (0.26%) upward. This increase is notable as the stock has outperformed its sector by 1.05% today. Additionally, the stock's performance over the past month shows a gain of 0.96%, which, while modest, indicates a positive trend compared to the broader market.<BR><BR>However, it is important to consider the context of the stock's performance. Over the year-to-date (YTD), the stock has declined by 3.65%, contrasting with a significant gain of 8.92% in the Sensex. This suggests that while there may be short-term gains, the stock has struggled to maintain momentum over a longer period.<BR><BR>The stock is currently trading above its 5-day, 20-day, 50-day, and 200-day moving averages, which typically indicates a bullish trend. However, it is below its 100-day moving average, which could signal some underlying weakness. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 54.79% compared to the 5-day average, which may indicate a lack of confidence among investors.<BR><BR>In summary, while Veerhealth Care's stock is experiencing a slight rise today and has shown some positive movement in the short term, the overall trend reflects challenges in the longer term, particularly in terms of investor participation and YTD performance.